Alto Neuroscience(ANRO) - 2024 Q2 - Quarterly Results

Exhibit 99.1 1 Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights – Completed enrollment of 301 patients in Phase 2b MDD study for ALTO-100; Investor Day focused on ALTO-100 planned for September 9, 2024; topline data expected in October 2024 – – Initiated multiple Phase 2 studies: ALTO-101 in schizophrenia, ALTO-203 in MDD with anhedonia, and ALTO-100 in bipolar depression – – Reported positive Phase 1 data on transdermal formulation of our novel PDE4 inhibitor, ...